Blog Index
The journal that this archive was targeting has been deleted. Please update your configuration.

Alhydrogel® Literature

Recommended reading about aluminum hydroxide:

Hem, S.L. and White, J.L.
Characterization of Aluminium Hydroxide for Use as an ADJUVANT in Parenteral Vaccines.
J. Parent. Sci. Techn. 1984, 38 (1), 2-11.

Hem, S.L., Klepak, P. and Lindblad, E.B. (2004) + (2005).
Monograph: AluminumHydroxide ADJUVANT in: Handbook of Pharmaceutical Excipients
Pharmaceutical Press Ltd., London.

Lindblad, E.B. (2004)
Aluminium ADJUVANTS – in Retrospect and Prospect
VACCINE 22 (27-28) 3658-3668.

Lindblad, E.B. (2004)
Aluminium Compounds for Use in Vaccines
Immunol. Cell Biol. 82 (5) 497-505.

Lindblad, E.B. (2006)
Are mineral ADJUVANTS triggering TLR2/TLR4 on dendriticcells by a secondary cascade reaction in vivothrough the action of heat shock proteins and danger signals? (Editorial Letter).
VACCINE 24 : 697-698.

Leenaars, P.P.A.M.; Hendriksen, C.F.M.; de Leeuw, W.A.; Carat, F.; Delahaut, P.; Fischer, R.; Halder, M.; Hanley, W.C.; Hartinger, J.; Hau, J.; Lindblad, E.B.; Nicklas, W.; Outschoorn, I.M. and Stewart-Tull, D.E.S. (1999).
The Production of Polyclonal Antibodies in Laboratory Animals.
The Report and Recommendations of ECVAM/FELASA Workshop 35.
ATLA 27: 70-102.

Shirodkar, S.; Hutchinson, R.L.; Perry, D.L.; White, J.L. and Hem, S.L.
Aluminium Compounds Used as ADJUVANTS in Vaccines.
Pharm. Res. 1990, 7 (12), 1282-1288.

Johnston, C.F.; Wang, S-L. and Hem, S.L.
Measuring the surface area of aluminium hydroxide ADJUVANT.
J. Pharm. Sci.2002, 91 (7) 1702-1706.

McCandlish, I.A.P.; Thompson, H. and Wright, N.G.
Vaccination Against Canine Bordetellosisusing an Aluminium Hydroxide ADJUVANT Vaccine.
Res. Vet. Sci. 1978, 25, 51-57.

Seeber, S.J.; White, J.L. and Hem, S.L.
Predicting the adsorption of proteins by aluminium-containing ADJUVANTS.
Vaccine 1991, 9, 201-203.

Iyer, S.; Robinett, R.S.R.; HogenEsch, H. and Hem, S.L.
Mechanism of adsorption of hepatitis B surface antigen by aluminium hydroxide ADJUVANT.
Vaccine2004, 22, 1475-1479.

Mannhalter, J. W.; Neychev, H.O.; Zlabinger, G.J.; Ahmad, R. and Eibl, M.M.
Modulation of the human immune response by the non-toxic and non-pyrogenicADJUVANT aluminium hydroxide: Effect on antigen uptake and antigen presentation.
Clin. Exp. Immunol. 1985, 61 (1), 143-151.

Iyer, S.; HogenEsch, H. and Hem, S.L.
Effect of the degree of phosphate substitution in aluminium hydroxide ADJUVANT on the adsorption of phosphorylatedproteins.
Pharm. Dev. Tech.2003, 8, 81-86.

Burrell, L.S.; Lindblad, E.B.; White, J.L. and Hem, S.L. (1999).
Stability of Aluminium-Containing ADJUVANTS to Autoclaving.
VACCINE17: 2599-2603.

Weeke, B.; Weeke, E. and Løwenstein, H.
The Adsorption of Serum Proteins to Aluminium Hydroxide Gel Examined by Means of Quantitative Immunoelectrophoresis in Quantitative Immunoelectrophoresis new developments and applications. (Ed. Axelsen, N.H.) 1975, 149-154. Universitetsforlaget.

Katz, J.B.; Hanson, S.K.; Patterson, P.A. and Stoll, I.R.
In vitro assessment of viral antigen content in inactivated aluminium hydroxide ADJUVANTed vaccines.
J. Virol. Methods1989, 25, 101-108.

Jankovic, D.; Caspar, P.; Zweig, M.; Garcia-Moll, M.; Showalter, S.D.; Vogel, F.R. and Sher, A.
Adsorption to aluminium hydroxide promotes the activity of IL-12 as an ADJUVANT for antibody as well as type 1 cytokine responses to HIV-1 gp120.
J. Immunol. 1999, 163: 4481-4488.

Rimaniol, A-C.; Gras, G.; Verdier, F.; Capel, F.; Grigoriev, V.B.; Porcheray, F.; Sauzeat, E.; Fournier, J.-G.; Clayette, P.; Siegrist, C.-A. and Dormont. D.
Aluminium hydroxide ADJUVANT induces macrophage differentiation towards a specialized antigen-presenting cell type.
Vaccine 2004 22: 3127-3135.

Butler, N.R.; Voyce, M.A.; Burland, W.L. and Hilton, M.L.
Advantages of Aluminium Hydroxide Adsorbed Combined Diphtheria, Tetanus, and Pertussis Vaccines for the Immunization of Infants.
Brit. Med. J. 1969, 1, 663-666.

Shi, Y.; HogenEsch, H.; Regnier, F.E. and Hem, S.L.
Detoxification of endotoxin by aluminium hydroxide ADJUVANT.
Vaccine 2001, 19 :1747-1752

Content